why choose us

First received: September 06, 2023

Clinical Trial: Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Locally Advanced Intrahepatic Cholangiocarcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 1 Trial: Safety & Preliminary Efficacy of Segmental Ablative Radioembolization With Tremelimumab Plus Durvalumab in Patients With Unresectable, Non-Metastic Cholangiocarcinoma Who Are Not Ca

Brief Summary: This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (bile ducts in the liver) cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are not candidates for curative therapy.Cholangiocarcinoma is a rare but aggressive cancer with limited curative options outside of surgery.Immunotherapy has shown modest…

Read more